EP3727362A4 - Promédicaments lipidiques d'acide mycophénolique et leurs utilisations - Google Patents
Promédicaments lipidiques d'acide mycophénolique et leurs utilisations Download PDFInfo
- Publication number
- EP3727362A4 EP3727362A4 EP18890811.5A EP18890811A EP3727362A4 EP 3727362 A4 EP3727362 A4 EP 3727362A4 EP 18890811 A EP18890811 A EP 18890811A EP 3727362 A4 EP3727362 A4 EP 3727362A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- mycophenolic acid
- medicinal products
- acid lipid
- lipid medicinal
- products
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
- C07D307/88—Benzo [c] furans; Hydrogenated benzo [c] furans with one oxygen atom directly attached in position 1 or 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Transplantation (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762607749P | 2017-12-19 | 2017-12-19 | |
| US201862724274P | 2018-08-29 | 2018-08-29 | |
| US201862768583P | 2018-11-16 | 2018-11-16 | |
| PCT/US2018/066585 WO2019126378A1 (fr) | 2017-12-19 | 2018-12-19 | Promédicaments lipidiques d'acide mycophénolique et leurs utilisations |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP3727362A1 EP3727362A1 (fr) | 2020-10-28 |
| EP3727362A4 true EP3727362A4 (fr) | 2021-10-06 |
Family
ID=66994291
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP18890811.5A Pending EP3727362A4 (fr) | 2017-12-19 | 2018-12-19 | Promédicaments lipidiques d'acide mycophénolique et leurs utilisations |
Country Status (2)
| Country | Link |
|---|---|
| EP (1) | EP3727362A4 (fr) |
| WO (1) | WO2019126378A1 (fr) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11883497B2 (en) | 2017-08-29 | 2024-01-30 | Puretech Lyt, Inc. | Lymphatic system-directing lipid prodrugs |
| EP3675838A4 (fr) | 2017-08-29 | 2021-04-21 | PureTech LYT, Inc. | Promédicaments lipidiques orientant vers le système lymphatique |
| CN109851593B (zh) * | 2019-02-01 | 2021-04-16 | 沈阳药科大学 | 基于淋巴介导转运的甘油三酯前药及其制备方法 |
| US12569438B2 (en) | 2019-07-29 | 2026-03-10 | Georgia Tech Research Corporation | Nanomaterials containing constrained lipids and uses thereof |
| JP7699128B2 (ja) * | 2019-12-06 | 2025-06-26 | ガイド セラピューティクス,エルエルシー | ナノマテリアル |
| US12435035B2 (en) | 2020-01-09 | 2025-10-07 | Guide Therapeutics, Llc | Nanomaterials |
| IL303845A (en) | 2021-01-20 | 2023-08-01 | Beam Therapeutics Inc | Nanomaterials include a degradable property |
| WO2024019936A1 (fr) | 2022-07-20 | 2024-01-25 | Beam Therapeutics Inc. | Nanomatériaux comprenant des triols |
| CN120983421A (zh) * | 2025-09-08 | 2025-11-21 | 齐鲁工业大学(山东省科学院) | 霉酚酸甲酯在制备抗血栓药物中的应用 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017041139A1 (fr) * | 2015-09-08 | 2017-03-16 | Monash University | Promédicaments ciblant la lymphe |
| WO2019046491A1 (fr) * | 2017-08-29 | 2019-03-07 | Ariya Therapeutics, Inc. | Promédicaments lipidiques orientant vers le système lymphatique |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6013665A (en) | 1997-12-16 | 2000-01-11 | Abbott Laboratories | Method for enhancing the absorption and transport of lipid soluble compounds using structured glycerides |
| EP1389617B1 (fr) | 2001-04-27 | 2007-01-03 | Zenyaku Kogyo Kabushiki Kaisha | Compose heterocyclique et agent antitumoral contenant ce dernier en tant qu'ingredient actif |
| TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
| WO2004019973A1 (fr) | 2002-08-14 | 2004-03-11 | Atugen Ag | Nouvelle mise en application de la proteine kinase n beta |
| KR20070087266A (ko) | 2003-04-03 | 2007-08-28 | 세마포르 파머슈티컬즈, 아이엔씨. | 피아이-3 키나아제 억제제 프로드러그 |
| CN1832939B (zh) | 2003-05-30 | 2010-04-28 | 杰明X医药品加拿大公司 | 用于治疗癌症或病毒病的三杂环化合物、组合物和方法 |
| US7173015B2 (en) | 2003-07-03 | 2007-02-06 | The Trustees Of The University Of Pennsylvania | Inhibition of Syk kinase expression |
| SI2612862T1 (sl) | 2004-05-13 | 2017-04-26 | Icos Corporation | Kinazolini kot inhibitorji humane fosfatidilinozitol 3-kinaze delta |
| DE602006010979D1 (de) | 2005-01-19 | 2010-01-21 | Rigel Pharmaceuticals Inc | Prodrugs aus 2,4-pyrimidindiamin-verbindungen und ihre verwendungen |
| EP1888550B1 (fr) | 2005-05-12 | 2014-06-25 | AbbVie Bahamas Ltd. | Promoteurs d'apoptose |
| GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| US7402325B2 (en) | 2005-07-28 | 2008-07-22 | Phoenix Biotechnology, Inc. | Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander |
| BRPI0617162B8 (pt) | 2005-10-07 | 2021-05-25 | Exelixis Inc | compostos inibidores de fosfatidilinositol 3-quinase composições farmacêuticas que os contem e métodos de uso dos mesmos |
| CN103626742B (zh) | 2005-11-01 | 2017-04-26 | 塔格根公司 | 激酶的联-芳基间-嘧啶抑制剂 |
| EP2455382B1 (fr) | 2005-12-13 | 2016-10-26 | Incyte Holdings Corporation | Pyrrolo[2,3-b]pyridines et pyrrolo[2,3-b]pyrimidines à substitution hétéroaryle en tant qu'inhibiteurs de la janus kinase |
| JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
| US20090023805A1 (en) * | 2006-02-13 | 2009-01-22 | Anne Claire Marrast | Method of administration |
| MX2008013578A (es) | 2006-04-26 | 2009-03-23 | Hoffmann La Roche | Derivados de tieno [3,2-d]pirimidina utiles como inhibidores de fosfatidilinositol 3-cinasa(p13k). |
| WO2008012246A1 (fr) | 2006-07-24 | 2008-01-31 | Basf Se | Azolylméthyloxiranes, leur utilisation dans la lutte contre des champignons phytopathogènes et agents les contenant |
| BRPI0622054B8 (pt) | 2006-09-22 | 2021-05-25 | Oxford Amherst Llc | composto e composição farmacêutica |
| HRP20151386T1 (hr) | 2007-03-12 | 2016-02-26 | Ym Biosciences Australia Pty Ltd | Fenil aminopirimidinski spojevi i njihova primjena |
| WO2008118802A1 (fr) | 2007-03-23 | 2008-10-02 | Regents Of The University Of Minnesota | Composés thérapeutiques |
| PE20090717A1 (es) | 2007-05-18 | 2009-07-18 | Smithkline Beecham Corp | Derivados de quinolina como inhibidores de la pi3 quinasa |
| KR100975520B1 (ko) | 2008-02-01 | 2010-08-12 | 종근당바이오 주식회사 | 마이코페놀레이트 모페틸의 개선된 제조방법 |
| US8158616B2 (en) | 2008-03-11 | 2012-04-17 | Incyte Corporation | Azetidine and cyclobutane derivatives as JAK inhibitors |
| KR101698028B1 (ko) | 2008-05-20 | 2017-01-26 | 노이로제스엑스, 인코포레이티드 | 수용성 아세트아미노펜 유사체 |
| US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
| WO2011051967A2 (fr) * | 2009-10-23 | 2011-05-05 | Alkem Laboratories Ltd | Compositions pharmaceutiques contenant du mycophénolate et leurs procédés de préparation |
| US20110213028A1 (en) * | 2010-02-26 | 2011-09-01 | Catabasis Pharmaceuticals, Inc. | Fatty acid mycophenolate derivatives and their uses |
| EP4578865A3 (fr) | 2014-08-12 | 2025-07-30 | Monash University | Promédicaments dirigeant la lymphe |
-
2018
- 2018-12-19 EP EP18890811.5A patent/EP3727362A4/fr active Pending
- 2018-12-19 WO PCT/US2018/066585 patent/WO2019126378A1/fr not_active Ceased
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017041139A1 (fr) * | 2015-09-08 | 2017-03-16 | Monash University | Promédicaments ciblant la lymphe |
| WO2019046491A1 (fr) * | 2017-08-29 | 2019-03-07 | Ariya Therapeutics, Inc. | Promédicaments lipidiques orientant vers le système lymphatique |
| EP3675838A1 (fr) * | 2017-08-29 | 2020-07-08 | Puretecch LYT, Inc. | Promédicaments lipidiques orientant vers le système lymphatique |
Non-Patent Citations (1)
| Title |
|---|
| See also references of WO2019126378A1 * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2019126378A1 (fr) | 2019-06-27 |
| EP3727362A1 (fr) | 2020-10-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3727362A4 (fr) | Promédicaments lipidiques d'acide mycophénolique et leurs utilisations | |
| EP3478693A4 (fr) | Dérivés d'acide boronique et leurs utilisations thérapeutiques | |
| MA53650A (fr) | Lipides peg et leurs utilisations | |
| MA53652A (fr) | Lipides peg de haute pureté et leurs utilisations | |
| EP3817769A4 (fr) | Anticorps anti-cd47 humains et leurs utilisations | |
| EP3891183A4 (fr) | Anticorps anti-claudine et leurs utilisations | |
| EP3759143A4 (fr) | Anticorps anti-tigit et leurs utilisations | |
| EP3625263A4 (fr) | Anticorps anti-galectine-9 et leurs utilisations | |
| EP3720502A4 (fr) | Produits cytobiologiques et leurs utilisations thérapeutiques | |
| EP3370770A4 (fr) | Formulations sous-cutanée d'anticorps anti-cd38 et leurs utilisations | |
| MA47789A (fr) | Anticorps anti-phf-tau et leurs utilisations | |
| EP3481430A4 (fr) | Conjugués de type acide nucléique et leurs utilisations | |
| EP3475449A4 (fr) | Étalons d'acide nucléique acellulaire et leurs utilisations | |
| EP3518971A4 (fr) | Formulations thérapeutiques d'anticorps et de protéines et leurs utilisations | |
| MA49886A (fr) | Anticorps anti-par2 et leurs utilisations | |
| EP3681912A4 (fr) | Anticorps spécifiques d'axl et leurs utilisations | |
| MA45125A (fr) | Anticorps anti-alpha-synucléine et leurs utilisations | |
| EP3555076A4 (fr) | Nouveaux dérivés de l'acide phényl propionique et leurs utilisations | |
| EP3645563A4 (fr) | Anticorps anti-fam19a5 et leurs utilisations | |
| EP3790586A4 (fr) | Anticorps anti-dll3 et leurs utilisations | |
| EP3672987A4 (fr) | Anticorps anti-apéline et leurs utilisations | |
| EP3380525A4 (fr) | Formulations pharmaceutiques et leurs procédés d'utilisation | |
| EP3850012A4 (fr) | Anticorps anti-tnfrsf9 et leurs utilisations | |
| EP3755714A4 (fr) | Anticorps anti-angiopoïétine-2 et leurs utilisations | |
| EP3894440A4 (fr) | Anticorps anti-il-27 et leurs utilisations |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
| 17P | Request for examination filed |
Effective date: 20200717 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| AX | Request for extension of the european patent |
Extension state: BA ME |
|
| DAV | Request for validation of the european patent (deleted) | ||
| DAX | Request for extension of the european patent (deleted) | ||
| A4 | Supplementary search report drawn up and despatched |
Effective date: 20210902 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
| 17Q | First examination report despatched |
Effective date: 20220614 |
|
| REG | Reference to a national code |
Ref country code: DE Ref legal event code: R079 Free format text: PREVIOUS MAIN CLASS: A61K0031138000 Ipc: A61K0045060000 |
|
| REG | Reference to a national code |
Ref country code: DE Ref legal event code: R079 Free format text: PREVIOUS MAIN CLASS: A61K0045060000 Ipc: A61K0047540000 |
|
| GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
| RIC1 | Information provided on ipc code assigned before grant |
Ipc: C07D 307/88 20060101ALI20241009BHEP Ipc: A61K 47/54 20170101ALI20241009BHEP Ipc: A61K 45/06 20060101AFI20241009BHEP |
|
| RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61P 19/02 20060101ALI20241011BHEP Ipc: A61P 25/00 20060101ALI20241011BHEP Ipc: A61P 1/00 20060101ALI20241011BHEP Ipc: A61P 37/06 20060101ALI20241011BHEP Ipc: A61P 37/00 20060101ALI20241011BHEP Ipc: C07D 307/88 20060101ALI20241011BHEP Ipc: A61K 45/06 20060101ALI20241011BHEP Ipc: A61K 47/54 20170101AFI20241011BHEP |
|
| INTG | Intention to grant announced |
Effective date: 20241029 |
|
| RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: MONASH UNIVERSITY Owner name: SEAPORT THERAPEUTICS, INC. |
|
| GRAJ | Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted |
Free format text: ORIGINAL CODE: EPIDOSDIGR1 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
| GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
| INTC | Intention to grant announced (deleted) | ||
| RAP3 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: MONASH UNIVERSITY Owner name: SEAPORT THERAPEUTICS, INC. |
|
| INTG | Intention to grant announced |
Effective date: 20250318 |
|
| GRAJ | Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted |
Free format text: ORIGINAL CODE: EPIDOSDIGR1 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
| GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
| INTC | Intention to grant announced (deleted) | ||
| INTG | Intention to grant announced |
Effective date: 20250804 |
|
| GRAJ | Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted |
Free format text: ORIGINAL CODE: EPIDOSDIGR1 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
| INTC | Intention to grant announced (deleted) | ||
| GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
| INTG | Intention to grant announced |
Effective date: 20260129 |